Eccogene, a global clinical-stage biotechnology company developing therapies for cardiometabolic diseases and inflammatory disorders, today announced that the first patient has been enrolled in China in the global Phase III clinical program for elecoglipron (AZD5004/ECC5004).   Elecoglipron is an investigational, once-daily, oral small molecule GLP-1 receptor agonist for the treatment of cardiometabolic diseases. The extensiveRead More

Eccogene, a global clinical-stage biotechnology company developing therapies for cardiometabolic diseases and inflammatory disorders, today announced that it has received a $50 million milestone payment from AstraZeneca. The milestone payment was triggered by the initiation of the global Phase 3 clinical program of elecoglipron (AZD5004/ECC5004). Elecoglipron is an investigational, once-daily, oral small molecule GLP-1 receptorRead More

Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions, today announced that data from a Phase 1b study conducted in China evaluating elecoglipron (AZD5004/ECC5004), an oral small-molecule GLP-1 receptor agonist, will be presented in a late-breaking poster presentation at the 2026 Scientific Sessions of the American DiabetesRead More

Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions, today announced that the first patient has been enrolled in MIST, the company’s Phase 2a clinical trial evaluating ECC4703 as an adjunct to semaglutide in adults with obesity. “While GLP-1–based therapies have established a new standard of care,Read More

Elecoglipron demonstrated a favorable safety and tolerability profile in Chinese adults living with obesity/overweight with or without type 2 diabetes mellitus (T2DM), consistent with that of the GLP-1 receptor agonist class Pharmacokinetic results in this study were comparable with the prior data generated from global Phase 1 clinical studies, supporting potential use of a consistentRead More

Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions, today announced that the first patient has been enrolled in MOSAIC, the company’s Phase 2a clinical trial evaluating ECC4703, ECC0509 and their combination in adults with MRI-based or clinically defined metabolic dysfunction-associated steatohepatitis (MASH). The MOSAIC trial isRead More

Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for MOSAIC, a Phase 2a trial evaluating ECC4703, ECC0509 and their combination in adults with presumed metabolic dysfunction-associated steatohepatitis (MASH).Read More

Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions, today announced that the first patient has been dosed in a Phase 1b clinical trial of AZD5004/ECC5004 in China. The earlier Phase 1 trial of AZD5004/ECC5004 was conducted in the U.S. only and this trial in China isRead More

Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions, today announced that preclinical data from a combination study of its wholly owned, highly selective liver-targeting THR-ß full agonist, ECC4703, together with a GLP-1 receptor agonist were selected for a late-breaking poster presentation at the American Diabetes Association’sRead More

Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions, today announced the formation of its Scientific Advisory Board (SAB), comprised of four renowned cardiometabolic disease experts. The SAB will serve as a strategic resource to Eccogene as it continues to advance its pipeline of novel oral smallRead More